DENND3

Across TCGA pan-cancer cohorts, DENND3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DENND3 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DENND3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DENND3 expression acts as an unfavorable survival marker.

PDAC, COAD, and CCRCC are the cancer types where DENND3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.281	0.529	<.001	100	view →
COAD	DFS	Median	II,III,IV	0.918	1.000	.011	30	view →
CCRCC	OS	Quartile	II,III,IV	0.617	1.000	.003	15	view →
LUAD	DFS	Quartile	III,IV	0.243	0.790	.013	10	view →
LSCC	DFS	Tertile	II,III,IV	0.542	0.861	.022	9	view →
GBM	OS	Median	All	0.271	0.511	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DENND3–PDAC (DFS)

Open the PDAC breakdown →